312 related articles for article (PubMed ID: 22144664)
1. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
2. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; LogiƩ A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
3. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
[TBL] [Abstract][Full Text] [Related]
5. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Yoon YK; Kim HP; Han SW; Hur HS; Oh DY; Im SA; Bang YJ; Kim TY
Mol Cancer Ther; 2009 Sep; 8(9):2526-36. PubMed ID: 19755509
[TBL] [Abstract][Full Text] [Related]
6. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
Sale MJ; Cook SJ
Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
[TBL] [Abstract][Full Text] [Related]
7. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
8. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
10. Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Chen JQ; Lee JH; Herrmann MA; Park KS; Heldman MR; Goldsmith PK; Wang Y; Giaccone G
Mol Cancer Ther; 2013 Nov; 12(11):2601-13. PubMed ID: 23979919
[TBL] [Abstract][Full Text] [Related]
11. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Zhang D; LaFortune TA; Krishnamurthy S; Esteva FJ; Cristofanilli M; Liu P; Lucci A; Singh B; Hung MC; Hortobagyi GN; Ueno NT
Clin Cancer Res; 2009 Nov; 15(21):6639-48. PubMed ID: 19825949
[TBL] [Abstract][Full Text] [Related]
13. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
15. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu ZH; Hang JB; Hu JA; Gao BL
Int J Clin Exp Pathol; 2013; 6(8):1493-504. PubMed ID: 23923067
[TBL] [Abstract][Full Text] [Related]
16. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
17. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
18. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
20. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
[Next] [New Search]